At Silica Corpora, we are De Novo Antibody Specialists, designing the next generation of antibody therapeutics. A single amino sequence and just few weeks is all we need to intelligently generate leading candidates ready for development. This means fewer trials and reduced animal testing in pre-clinical stages. So why wait? Go De Novo! #BioTech #AI #DrugDesign #SilicaCorpora #GoDeNovo #FutureofHealthcare #Teamwork #Innovation #CompanyCulture
Silica Corpora’s Post
More Relevant Posts
-
CEO | Board Director | Cell and Gene Therapy |Rare Disease Patient Advocate |Global Network | Women's Leadership
....Metagenomi expects net proceeds of about $87 million if it prices at $16 per share, the midpoint of its proposed range disclosed Monday morning in an SEC filing. The biotech will likely go public later this week by selling 6.25 million shares. There’s a chance its proceeds could balloon if the company upsizes before landing on Nasdaq as “MGX,” as CG Oncology, ArriVent Biopharma and Alto Neuroscience did in the past two weeks. The Moderna-allied Metagenomi would be one of the only biotechs to go public in the past two years before it had any therapeutic programs in human testing, and one of the only gene editing startups to do so either...... #preclinical #IPO #publicmarkets #cellandgenetherapy #genetherapy #geneediting #advancedtherapies #regenerativemedicine #biotech #biotechnology #lifesciences #healthcare #researchanddevelopment #leadoptimization Brian Thomas Bayer RA Capital Management Humboldt Fund Novo Holdings Ionis Pharmaceuticals, Inc. Affini-T Therapeutics #exvivo #immunooncology #autoimmune #raredisease #rarediseases #hemophilia #400mtodate
-
Today is the last day of FormuTech Summit 2024 in Madrid! If you’re attending make sure you find our business development manager and senior scientist Qiong Wu PhD if you're interested in GMP-certified TEM services, quality control analyses of nanoparticles, or simply want to say hello. 🔬 Key discussions at the conference have included: 🔬 Empowering mRNA innovations for therapeutic impact 💡 Mastering LNP characterization for efficacy & safety 🌍 Tackling global manufacturing challenges for a resilient production landscape 🧬 Exploring LNPs in gene editing & CRISPR applications 📋 Optimizing CMC for consistent mRNA therapeutic quality ⚖️ Navigating technical and regulatory hurdles. #FormuTech2024 #mRNA #LNP #Pharmaceuticals #GeneTherapy #Innovation #ProcessDevelopment #TEM
-
-
📢 𝐒𝐚𝐧𝐠𝐚𝐦𝐨 𝐬𝐞𝐜𝐮𝐫𝐞𝐬 𝐔𝐒$𝟓𝟎𝐌 𝐮𝐩𝐟𝐫𝐨𝐧𝐭 𝐢𝐧 𝐧𝐞𝐮𝐫𝐨𝐝𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐯𝐞 𝐩𝐚𝐜𝐭 𝐰𝐢𝐭𝐡 𝐑𝐨𝐜𝐡𝐞'𝐬 𝐆𝐞𝐧𝐞𝐧𝐭𝐞𝐜𝐡 🔔 📣 𝐈𝐧 𝐀𝐮𝐠𝐮𝐬𝐭 𝟐𝟎𝟐𝟒, Sangamo Therapeutics, Inc. secures 𝐔𝐒$𝟓𝟎𝐌 💰upfront in #neurodegenerative pact with Roche's Genentech. Sangamo will be responsible for a #technology transfer and specific #preclinical activities, while Genentech will take on #clinicaldevelopment🏥, regulatory efforts, and #manufacturing💊 and global commercialization activities. The global licensing deal gives the Big Pharma's Genentech unit exclusive rights to Sangamo’s proprietary zinc finger repressors. The DNA-binding technology takes aim at the tau gene which plays a vital role in Alzheimer’s #disease 💊and a second undisclosed neurology target. Genentech has also snagged exclusive rights to Sangamo’s neurotropic adeno-associated virus (AAV) capsid, known as STAC-BBB. The tech has shown potent #bloodbrain barrier penetration and brain transduction in animal models 🐀 and is designed to expand delivery beyond capsids that are currently delivered intrathecally via an injection into the spinal canal ☤. 𝐋𝐨𝐨𝐤 𝐚𝐭 𝐨𝐮𝐫 𝐂𝐨𝐫𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐑𝐞𝐩𝐨𝐫𝐭 👉: https://bit.ly/4dBCpPc #Regulatory #MSMEs #Biotechnology #ViralVector #DNABinding, #ClinicalDevelopment #prophecymarketinsights
-
-
Today marks the day of our webinar, "2023 Annual Meeting Poster Awardee Spotlight," featuring Anastasia Kremer and Linda Popella. Join us from 11-12 pm EST for a deep dive into their research. Kremer will speak on siRNA therapy for ex vivo treatment, and Popella will share insights on high-susceptibility targets of programmable RNA antibiotics. Don't miss this chance to stay informed about the latest developments in oligonucleotide therapeutics! https://lnkd.in/gHNPiiwc #OTS #oligotherapeutics #oligonucleotides #biotech #biotechnology #science #research #biology #pharma #sirna #rna #webinar #currentscience #healthinsights #stemcells
-
-
At #ASGCT2024, our CSO John Murphy sat down with CGTLive to discuss the latest preclinical data from our lead program, ABO-101, and its therapeutic potential to address primary hyperoxaluria type 1. 🎤 Watch the interview here: https://lnkd.in/ecRNDrNb #geneediting #CRISPR #biotech #primaryhyperoxaluria
John Murphy, PhD, on Using Gene Editing to Tackle Primary Hyperoxaluria Type 1
cgtlive.com
-
Don't miss our webinar on Monday 30th September, my colleague Jin Lu will discuss the latest advancements in therapeutic protein expression. #Biologics #Lonza #LonzaInYourLab #Biotechnology
Join us on Monday, September 30th at 5 PM CET | 11 AM ET for a webinar on "Innovative Solutions for Enhancing Biotherapeutic Expression and Development" hosted by Lonza in collaboration with Genetic Engineering & Biotechnology News. In this session, Jin Lu, Ph.D., Senior Technical Support Manager in Licensing at Lonza Biologics, will explore the latest advancements in the GS® expression toolbox. Dr. Lu will share insights into how these technologies are accelerating the successful development of biotherapeutics, from discovery through to commercial supply. Key topics include: - Optimizing the GS System® for diverse protein expression - Enhancing transient titers with GS Discovery® - Leveraging the GS Effex® cell line for potent cancer immunotherapies - Overcoming industry-wide challenges in bispecific development with the bYlok® format Don't miss this opportunity to gain valuable knowledge and participate in a live Q&A with our expert speaker. Register Now https://lnkd.in/etGJaHw5 #Webinar #Biotech #LonzaExpressionSystems #Lonza #LonzaInYourLab
-
-
Senior Director Client & Contract Management at CDMO Wacker Biotech (BD/PM/Contracting)
Meet the #CDMO Experts in Boston for pDND, mRNA, LNP - Talk to our Scientists about YOUR Project at Boston Biotech Week!
We’re looking forward to participating in Boston Biotech Week and the BioProcess International/Cell & Gene Therapy International conference, September 21-26 in Boston at the Hynes Convention Center. If you’re attending and in town, we hope you’ll reach out and connect! Our Wacker Biotech team – John Childers, Junru Xue and Ryan Beaubien, MBA – will be at booth no. 1702 to speak with you about your pDNA/mRNA/LNP, protein and vaccine project needs. With five state-of-the-art facilities worldwide, we provide highly customized, reliable and flexible solutions for biologics production at every stage of the biopharma lifecycle, at qualities ranging from research-grade to GMP and scales from 6 L to 1500 L. Also come hear our San Diego head of process development, Mack Kuo, Ph.D., on the Innovation and Community Stage on Wednesday, September 25 at 3:10 p.m. EST. Mack will speak about our proprietary plug-and-play PLASMITEC® platform, which utilizes a strain of E. coli specifically engineered for high-quality nucleic acid production well-suited for viral vector, mRNA, and other therapeutic applications. See you soon in Boston! #BPIconf #BiotechWeekBoston #biopharma #biotech #biologics
-
-
Can you make sense of antisense therapies? 🧐 Antisense therapies are single-stranded synthetic RNA or DNA molecules that bind to complementary nucleic acid sequences to modulate protein expression. 🧬 Isarna Therapeutics GmbH is developing a portfolio of antisense therapies to treat eye diseases. 👁️ Labiotech was in conversation with Rene Rückert, M.D. MBA, COO of Isarna Therapeutics, who discussed the potential role of these drugs in tackling diseases. 🎧 Tune into the latest episode of the Beyond Biotech Podcast to know more about this novel technology! 👇 https://lnkd.in/dhUnhhgH #BeyondBiotechPodcast #antisensetherapies #RNA #DNA #proteinexpression #eyediseases #biotechinnovation
-
-
𝗜𝘀 𝗥𝗡𝗔 𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝘁𝗵𝗲 𝗵𝗶𝗱𝗱𝗲𝗻 𝗸𝗲𝘆 𝘁𝗼 𝗯𝗿𝗲𝗮𝗸𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀? Behind every RNA-based treatment, a complex folding process can either drive success or lead to failure. In our latest eBlog, we reveal how RNA’s intricate structure influences the stability of vaccines, the success of small molecule drugs, and the power of siRNA therapies. The answers could redefine how we design the next generation of RNA medicines. Discover the science behind it all in our eBlog! https://lnkd.in/gJpw8Yza #RNAInnovation #Therapeutics #Genomics #Biotech #RNAstructure #Eclipsebio
-
-
Matt Orley, Big Paper Strategy LLC took excellent illustrated notes at our PDA - Parenteral Drug Association Annual meeting! Experts shared insights into techniques for manufacturing, testing, and qualifying adeno-associated virus (AAV) products. Additionally, best practices and strategies for navigating ATMP regulatory submissions, the importance of interpreting and applying multimodal CMC data, and its analyses for the advancement of ATMP-related manufacturing were presented. Stephanie L., MBS, Operations Manager, Amgen. Anthony Blaszczyk, PhD, Senior Scientist Janmeet Anant, Ph.D., PMP, RAC, PhD, Senior Regulatory Consultant, MilliporeSigma Jeff Odum, CPIP, Practice Lead, ATMPs & Biologics, Genesis AEC The field of gene therapy is rapidly developing and expanding, with many new and innovative therapies to treat disease! #GenesisAEC #genetherapy #innovation #lifesciences #manufacturing
-
